Lung injury after cardiopulmonary bypass: Alternative treatment prospects

Xue-Mei Zheng; Zhuo Yang; Guang-Li Yang; Yan Huang; Jie-Ru Peng; Meng-Jun Wu

doi:10.12998/wjcc.v10.i3.753

Lung injury after cardiopulmonary bypass: Alternative treatment prospects

World J Clin Cases. 2022 Jan 21;10(3):753-761. doi: 10.12998/wjcc.v10.i3.753.

Authors

Xue-Mei Zheng¹, Zhuo Yang², Guang-Li Yang³, Yan Huang⁴, Jie-Ru Peng⁵, Meng-Jun Wu⁶

Affiliations

¹ School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China.
² Department of Pharmacy, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China.
³ Department of Medical Administration, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China.
⁴ National Institute of Drug Clinical Trial, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China.
⁵ Department of Medical Records Statistics, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China.
⁶ Department of Anesthesiology, The Affiliated Hospital, School of Medicine, Chengdu Women's and Children's Central Hospital, University of Electronic Science and Technology, Chengdu 610000, Sichuan Province, China. 3400164739@qq.com.

Abstract

Although the lung injury caused by cardiopulmonary bypass (CPB) has been extensively investigated, the incidence and mortality of lung injury after CPB remain a prominent clinical problem. The poor outcome has been attributed to multifactorial etiology, including the systemic inflammatory response and ischemia reperfusion (I/R) injury during CPB. Lung injury after CPB is a complex pathophysiological process and has many clinical manifestations of mild to severe disease. Which is associated with prognosis. To alleviate this lung injury, interventions that address the pathogenesis are particularly important. This review summarizes the pathogenesis, mechanism and treatment options of lung injury after CPB, such as lung protection with intralipid.

Keywords: Cardiopulmonary bypass; Intralipid; Lung injury; Pathogenesis; Systemic inflammatory response syndrome; Treatment.

Publication types

Review